Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients

Inclusion Criteria

• •For group 1 without trastuzumab :
• •Patients must be ≥ 18 years old
• •Patients with breast cancer stage I to III
• •Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, without trastuzumab
• •Patients must have a social security coverage
• •Patients able to speak, read and understand French
• •For group 2 with trastuzumab :
• •Patients must be ≥ 18 years old
• •Patients with breast cancer grade I to III
• •Patients who will receive (neo)adjuvant anthracyclines and weekly taxane, with trastuzumab
• •Patients must have a social security coverage
• •Patients able to speak, read and understand French